article thumbnail

Big Pharma's Hidden Business Model and How Your Company Funds It

Harvard Business Review

Since companies test their own products—an obvious conflict of interest—they naturally design clinical trials to maximize evidence that they are beneficial and minimize evidence they are harmful. See The Risks of Prescription Drugs (Columbia 2010). These cost employers even more in hidden ways.

article thumbnail

Retirement Planning Needs a Better UX

Harvard Business Review

The details of the proposed new rules are sure to raise questions about things like fee disclosures and conflicts of interest. The reality, however, is that this issue is deeply connected to how we make decisions on digital displays, which is of crucial importance to investors, businesses, and policy makers.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Integrating Maintenance of Board Certification and Health Systems’ Quality-Improvement Programs

Harvard Business Review

In addition to disclosing conflicts of interest, physicians attest to participating in the QIP and report their roles (see Table 2 ). From January 2010, when the quality review board became operational, to December 2012, 230 QIPs were reviewed and 168 (73%) of them were approved for Part IV MOC.

article thumbnail

At Olympus and Goldman Sachs, Two Very Different Whistleblowers

Harvard Business Review

For example, the SEC in 2010 had charged Goldman with misleading some of the parties to a billion dollar transaction (involving a complex derivative called a synthetic collateralized debt obligation), alleging specific facts about undisclosed conflicts of interest. Goldman settled within months for $550 million.

article thumbnail

The Growing Conflict-of-Interest Problem in the U.S. Congress

Harvard Business Review

While concerns about conflicts of interest regarding President Trump’s business holdings have received a lot of attention, resulting in proposed legislation to end loopholes for the commander in chief , there has been much less discussion of another source of conflicting interests: the investments of members of Congress.

article thumbnail

How Pharma Can Fix Its Reputation and Its Business at the Same Time

Harvard Business Review

The estimated return on these (fewer) products has itself declined substantially since 2010, from 10.1% Moreover, they should partner with other actors, including governments, NGOs, and private foundations, to build capacities into the pharma value chain while avoiding conflicts of interest.

article thumbnail

What You Should Know About Dodd-Frank and What Happens If It’s Rolled Back

Harvard Business Review

On February 3 President Trump issued an executive order directing the Treasury Department to conduct a sweeping review of financial regulation, including Dodd-Frank , the financial reform bill passed, in 2010, as part of the Obama administration’s response to the 2008 financial crisis and subsequent recession.